Sector
PharmaceuticalsOpen
₹57.9Prev. Close
₹57.59Turnover(Lac.)
₹5,459.1Day's High
₹60.44Day's Low
₹57.852 Week's High
₹60.7552 Week's Low
₹28.8Book Value
₹17.43Face Value
₹2Mkt Cap (₹ Cr.)
2,976.02P/E
26.51EPS
2.17Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 102.23 | 121.81 | 133.71 | 89.96 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 677.89 | 476.36 | 311.26 | 217.29 |
Net Worth | 780.12 | 598.17 | 444.97 | 307.25 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 1,112.42 | 791.98 | 560.83 | 547.5 |
yoy growth (%) | 40.45 | 41.21 | 2.43 | 21 |
Raw materials | -736.61 | -521.08 | -342.59 | -335.73 |
As % of sales | 66.21 | 65.79 | 61.08 | 61.32 |
Employee costs | -123.2 | -98.07 | -68.21 | -60.79 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 94.24 | 37.48 | 26.11 | 23.16 |
Depreciation | -28.11 | -34.43 | -33.39 | -33.56 |
Tax paid | 0 | -5.14 | 0 | 0 |
Working capital | -26.96 | 124.59 | -1.66 | 17.45 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 40.45 | 41.21 | 2.43 | 21 |
Op profit growth | 74.31 | 6.96 | -0.35 | -5.78 |
EBIT growth | 143.44 | 29.72 | -0.75 | 0.61 |
Net profit growth | 191.49 | 23.8 | 12.72 | 46.83 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 1,690.43 | 1,417.53 | 1,546.83 | 1,188.06 | 853.07 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,690.43 | 1,417.53 | 1,546.83 | 1,188.06 | 853.07 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 13.97 | 6.13 | 10.31 | 12.07 | 9.48 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,665.8 | 130.91 | 3,99,537.26 | 867.6 | 0.81 | 5,536.99 | 98.75 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,205.8 | 35.29 | 1,21,311.57 | 1,405.2 | 0.25 | 3,172.6 | 156.19 |
Cipla Ltd CIPLA | 1,500.05 | 32.61 | 1,21,119.62 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Divis Laboratories Ltd DIVISLAB | 4,547 | 76.67 | 1,20,781.57 | 531 | 0.66 | 2,259 | 507.93 |
Dr Reddys Laboratories Ltd DRREDDY | 6,853.2 | 26.69 | 1,14,348.41 | 1,034.8 | 0.58 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sushil Suri
Non-Exec. & Independent Dir.
Manoj Joshi
Non-Exec. & Independent Dir.
Bhupender Raj Wadhwa
Non-Exec. & Independent Dir.
Sukhcharan singh
Company Sec. & Compli. Officer
Vipul Kumar Srivatava
Whole-time Director
Sanjay Suri
Non-Exec. & Independent Dir.
Praveen Kumar Dutt
Non-Exec. & Independent Dir.
Savita
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Morepen Laboratories Ltd
Summary
Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L.The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre.The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing locatio
Read More
The Morepen Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹58.22 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Morepen Laboratories Ltd is ₹2976.02 Cr. as of 26 Jul ‘24
The PE and PB ratios of Morepen Laboratories Ltd is 26.51 and 3.31 as of 26 Jul ‘24
The 52-week high/low is the highest and lowest price at which a Morepen Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Morepen Laboratories Ltd is ₹28.8 and ₹60.75 as of 26 Jul ‘24
Morepen Laboratories Ltd's CAGR for 5 Years at 29.36%, 3 Years at -4.80%, 1 Year at 100.31%, 6 Month at 27.84%, 3 Month at 15.06% and 1 Month at 1.30%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.